AstraZeneca and Amgen quietly admit tezepelumab defeat as the Dupixent challenger heads to FDA

AstraZeneca and Amgen have blockbuster ambitions for their tezepelumab antibody, aiming to challenge the Regeneron and Sanofi giant Dupixent in asthma and related respiratory maladies. But as part of its second quarter update Thursday morning, the big British drugmaker quietly scuttled plans in another indication, raising doubt over how big a bite it will take out of the Dupixent pie.